Digital Biomarker Data Scientist - Parkinson’s​/Huntington’s disease; m​/f​/d

Let’s build a healthier future, together! By combining our unique strengths, we are redefining healthcare through sustainable action and innovation. For a behind-the-scenes look, check out this video to see how we at Roche are making personalized health care a reality.

The mySugr GmbH was acquired by Roche in 2017 and our Vienna office is one of Roche's global sites. You will be located here, in the heart of Vienna, no matter if you work on a mySugr®, Accu-Chek®, navify® or any other Roche product or solution. You can read more about the history of mySugr & Roche here.

We, the Digital Biomarker and Remote Patient Management (dBM & RPM) Chapter in Roche Information Solutions, are an integrated team of scientists, technologists, data analysts and operationalization experts, that leverages mobile technologies like smartphones and wearables to collect objective and continuous sensor data from patients in clinical trials and clinical care.

We co-create innovative digital biomarker concepts for sensitive and meaningful drug development endpoints, implement them in technology solutions, develop health related outcome measures, seek community- and regulatory acceptance of corresponding endpoints and provide end-to-end services to Biopharma companies and research institutes for the collection and analysis of digital endpoint data in clinical trials. Moreover, we are establishing the scientific foundations for disease monitoring and screening solutions in clinical practice.

This role will focus in particular on our Navify digital biomarker solutions for Parkinson’s and Huntington’s disease – see  for a description of the products. The following publications provide a good overview of the scientific foundations of the products:

Giboin, L.S., Simillion,

C., Rennig, J., Bamdadian,

A., Kinsella, F.C., Smith, A.V., McColgan, P., Lindemann, M., Lipsmeier,

F., Wild, E.J. and Dorn, J., 2025. A digital motor score for sensitive detection of progression in Huntington’s disease. Brain.

Taylor, K.I., Lipsmeier,

F., Scelsi, M.A. et al. Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab. npj Digit. Med. 8, 365 (2025).

• Lead statistical analysis activities to establish the psychometric properties, construct validity, test-retest reliability, and responsiveness of novel digital endpoints derived from mobile technologies
• Design and execute statistical analysis plans (SAPs) for clinical validation studies, utilizing longitudinal modeling techniques to track disease progression and evaluate treatment effects
• Develop robust statistical strategies to handle remote sensor data challenges, including non-compliance, variable wear time, and missing data
• Align validation workflows with industry frameworks, such as the Digital Medicine Society (DiME) V3 framework (Verification, Analytical Validation, Clinical Validation) and FDA DHT guidance

• Serve as the data scientific subject matter experts in pre-sales calls, sponsor meetings, and scientific advisory boards, effectively communicating the scientific rigor behind Navify solutions
• Collaborate directly with biopharma customers to understand their drug development pipelines and co-design optimal digital endpoint strategies for their clinical trials
• Translate complex statistical concepts and validation evidence into clear value propositions, supporting the commercial team in developing high-impact sales collateral and proposals
• Provide scientific and statistical support to address ad-hoc customer queries regarding data interpretation and trial design

• Contribute quantitative evidence…